This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPECAL0T9_M.jpg
Revenue was $71.43 million, beating the consensus estimate of $58.32M. Both net product revenue and cost of sales during the period were attributable to sales of RELYVRIO in the U.S. and ALBRIOZA in Canada.
“We continue to see strong engagement and interest from physicians and the ALS community and are encouraged that the vast majority of payors who have published formal policy decisions are providing broad access to RELYVRIO,” said co-CEO Joshua Cohen.
